Pfizer takeover is in the news on internet again today... It's a matter of time!

Quote








































One more confirmation:

http://www.bloomberg.com/news/2014-...-proposing-98-7-billion-astrazeneca-deal.html

The stock is up 10 bucks premarket.

This shows the power of the taxman. Pfizer doesn't want to repatriate their $ and toss it in to the bottomless pit that our government has become. The US debt rating will be lowered, again. Run for cover, we are no longer a business friendly country! That is the message in Pfizer's interest in AZ.
 




From the Financial Times in London. At the very least CNS looks like it will be sold off. PASCAL, THIS DEAL IS TOO DAMN GOOD FOR SHAREHOLDERS! MAKE IT HAPPEN!

High quality global journalism requires investment. Please share this article with others using the link below, do not cut & paste the article. See our Ts&Cs and Copyright Policy for more detail. Email ftsales.support@ft.com to buy additional rights. http://www.ft.com/cms/s/0/0cad0dd4-ce9c-11e3-ac8d-00144feabdc0.html#ixzz30Ai9mTlx

Shares in AstraZeneca jumped as much as 15 per cent on Monday morning after Pfizer confirmed its interest in a takeover of the UK pharmaceuticals group in what would be one of the biggest deals in the industry’s history.
The New York-listed maker of Viagra on Monday confirmed it had contacted AstraZeneca at the weekend in a fresh attempt to open talks after the UK group rebuffed an initial approach in January.
More
ON THIS STORY
Big pharma deals important to R&D
Drug innovation In the recovery room
John Gapper The future of pharma
AstraZeneca looks at $15bn of spin-offs
ON THIS TOPIC
Fast FT Pfizer confirms second AstraZeneca approach
Pfizer renews bid interest in AstraZeneca
AstraZeneca shareholders revolt over pay
UK science drive shaken by takeover fears
IN PHARMACEUTICALS
Mylan raises Meda offer to $9bn-plus
Novartis boosted by emerging markets
Deals fever grips pharma industry
Allergan hits back in pharma deals frenzy
Pfizer said it made a preliminary, non-binding indication of interest to the board of AstraZeneca in January for a cash-and-shares deal that valued the UK company’s equity at £58.8bn.
This approach, at £46.61 per AstraZeneca share, represented a “substantial” premium of about 30 per cent to the London-listed group’s closing share price on January 3. AstraZeneca shares were up 13 per cent at £46.14 on Monday morning having earlier reached as high as £47.13.
Pfizer renewed its interest on Saturday for a “possible transaction in which AstraZeneca shareholders would receive a significant premium” to the undisturbed share price as of April 17, before news reports of the initial talks emerged.
Pfizer said: “AstraZeneca again declined to engage. Pfizer is currently considering its options with respect to AstraZeneca.”
Under UK Takeover Panel rules, Pfizer now has until 5pm on May 26 to announce a firm intention to make an offer for AstraZeneca or walk away.

The US group said any combination of the two companies would have management teams based on both sides of the Atlantic, but have its headquarters in New York and be listed on the New York Stock Exchange.
The deal would mark the biggest takeover of a UK company and rekindle fears over the loss of industrial expertise and investment in the British life sciences sector.
Ian Read, chairman and chief executive of Pfizer, said: “We have great respect for AstraZeneca and its proud heritage as an innovation-driven biopharmaceutical business with a rich science-based foundation in both the United Kingdom and Sweden.”
He added: “The combination of Pfizer and AstraZeneca could further enhance the ability to create value for shareholders of both companies and bring an expanded portfolio of important treatments to patients.”
By going public about its approach, Pfizer was aiming to put pressure on AstraZeneca’s board to engage in talks, industry analysts said.
AstraZeneca on Monday said it was considering its response to the Pfizer statement and had no immediate comment.
Any deal would be the biggest pharma deal since Pfizer’s $111.8bn takeover of Warner-Lambert in 2000.
The move comes at a time of renewed corporate activity in the sector as drugmakers look to deploy large cash piles and cheap debt to strengthen their positions in an increasingly competitive market.
Analysts cite AstraZeneca’s growing potential in high-value cancer drugs as one of the main attractions for Pfizer. The US company’s desire to find a tax-efficient outlet for tens of billions of dollars in offshore cash is seen as another strong motivation.
In its statement on Monday, Pfizer said it believed synergies could be achieved through greater capital efficiency in the two companies’ operations and a more efficient tax structure. The merged company would operate “under a new UK-incorporated holding company [that] would not subject AstraZeneca’s non-US profits to US tax”, Pfizer said.
Pascal Soriot, AstraZeneca chief executive, last week set out plans for the possible sale or spin-off of non-core assets worth up to $15bn in an apparent attempt to shore up investor support for his turnround efforts after years of falling sales.
Shares in the company have climbed a quarter over the past six months amid rising optimism over its strengthening innovation pipeline.
Mergers and acquisitions in the healthcare sector have picked up in recent months after a subdued period. Last week, Valeant and the activist investor Bill Ackman teamed up to launch a $45bn unsolicited bid for Allergan, the maker of Botox, while GlaxoSmithKline and Novartis agreed a $20bn asset swap.
The value of healthcare deals is at more than $150bn globally for the year to date, according to data from Dealogic. The surge has helped push the overall M&A market above the $1tn mark – the first time since 2007 that it has reached that level by this point in the year.
Addressing reporters last week, Mr Soriot highlighted the risks involved in big mergers. “Large acquisitions sometimes can work but sometimes they are very disruptive, so I think we are better off focusing on what we do well and partnering in other areas,” he said.
AstraZeneca is at the heart of Britain’s life sciences sector, employing about 7,000 people in the country and accounting for more than 2 per cent of exported goods.
 




Financial Times of London article today.

Shares in AstraZeneca jumped as much as 15 per cent on Monday morning after Pfizer confirmed its interest in a takeover of the UK pharmaceuticals group in what would be one of the biggest deals in the industry’s history.
The New York-listed maker of Viagra on Monday confirmed it had contacted AstraZeneca at the weekend in a fresh attempt to open talks after the UK group rebuffed an initial approach in January.
More
ON THIS STORY
Big pharma deals important to R&D
Drug innovation In the recovery room
John Gapper The future of pharma
AstraZeneca looks at $15bn of spin-offs
ON THIS TOPIC
Fast FT Pfizer confirms second AstraZeneca approach
Pfizer renews bid interest in AstraZeneca
AstraZeneca shareholders revolt over pay
UK science drive shaken by takeover fears
IN PHARMACEUTICALS
Mylan raises Meda offer to $9bn-plus
Novartis boosted by emerging markets
Deals fever grips pharma industry
Allergan hits back in pharma deals frenzy
Pfizer said it made a preliminary, non-binding indication of interest to the board of AstraZeneca in January for a cash-and-shares deal that valued the UK company’s equity at £58.8bn.
This approach, at £46.61 per AstraZeneca share, represented a “substantial” premium of about 30 per cent to the London-listed group’s closing share price on January 3. AstraZeneca shares were up 13 per cent at £46.14 on Monday morning having earlier reached as high as £47.13.
Pfizer renewed its interest on Saturday for a “possible transaction in which AstraZeneca shareholders would receive a significant premium” to the undisturbed share price as of April 17, before news reports of the initial talks emerged.
Pfizer said: “AstraZeneca again declined to engage. Pfizer is currently considering its options with respect to AstraZeneca.”
Under UK Takeover Panel rules, Pfizer now has until 5pm on May 26 to announce a firm intention to make an offer for AstraZeneca or walk away.

The US group said any combination of the two companies would have management teams based on both sides of the Atlantic, but have its headquarters in New York and be listed on the New York Stock Exchange.
The deal would mark the biggest takeover of a UK company and rekindle fears over the loss of industrial expertise and investment in the British life sciences sector.
Ian Read, chairman and chief executive of Pfizer, said: “We have great respect for AstraZeneca and its proud heritage as an innovation-driven biopharmaceutical business with a rich science-based foundation in both the United Kingdom and Sweden.”
He added: “The combination of Pfizer and AstraZeneca could further enhance the ability to create value for shareholders of both companies and bring an expanded portfolio of important treatments to patients.”
By going public about its approach, Pfizer was aiming to put pressure on AstraZeneca’s board to engage in talks, industry analysts said.
AstraZeneca on Monday said it was considering its response to the Pfizer statement and had no immediate comment.
Any deal would be the biggest pharma deal since Pfizer’s $111.8bn takeover of Warner-Lambert in 2000.
The move comes at a time of renewed corporate activity in the sector as drugmakers look to deploy large cash piles and cheap debt to strengthen their positions in an increasingly competitive market.
Analysts cite AstraZeneca’s growing potential in high-value cancer drugs as one of the main attractions for Pfizer. The US company’s desire to find a tax-efficient outlet for tens of billions of dollars in offshore cash is seen as another strong motivation.
In its statement on Monday, Pfizer said it believed synergies could be achieved through greater capital efficiency in the two companies’ operations and a more efficient tax structure. The merged company would operate “under a new UK-incorporated holding company [that] would not subject AstraZeneca’s non-US profits to US tax”, Pfizer said.
Pascal Soriot, AstraZeneca chief executive, last week set out plans for the possible sale or spin-off of non-core assets worth up to $15bn in an apparent attempt to shore up investor support for his turnround efforts after years of falling sales.
Shares in the company have climbed a quarter over the past six months amid rising optimism over its strengthening innovation pipeline.
Mergers and acquisitions in the healthcare sector have picked up in recent months after a subdued period. Last week, Valeant and the activist investor Bill Ackman teamed up to launch a $45bn unsolicited bid for Allergan, the maker of Botox, while GlaxoSmithKline and Novartis agreed a $20bn asset swap.
The value of healthcare deals is at more than $150bn globally for the year to date, according to data from Dealogic. The surge has helped push the overall M&A market above the $1tn mark – the first time since 2007 that it has reached that level by this point in the year.
Addressing reporters last week, Mr Soriot highlighted the risks involved in big mergers. “Large acquisitions sometimes can work but sometimes they are very disruptive, so I think we are better off focusing on what we do well and partnering in other areas,” he said.
AstraZeneca is at the heart of Britain’s life sciences sector, employing about 7,000 people in the country and accounting for more than 2 per cent of exported goods.
 




Good luck to all of us. If Pfizer take it, and it's beginning to look like they will, they'll strip the meat to keep the marrow and throw the rest away to recoup the enormous buy out. Pfizer's a cancer.
 
























Top Bottom
Back
Quote